To better understand whether KIT can be viewed as a primary target for RTK inhibitors and other drugs, we used lentiviral vectors encoding shRNA against KIT to selectively downregulate KIT expression in two neuroblastoma cell lines expressing KIT at remarkably different levels. This evidence concerns the gene KIT and neuroblastoma.